A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
21
Enrollment
INDUSTRY
Sponsor class

Stopped The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved

Conditions

Interventions

Sponsor

Versartis Inc.